Therefore, we designed the NeoPembrOV trial to assess the effect of combining pembrolizumab with NACT and post-IDS therapy for advanced high-grade serous carcinoma (HGSC), and included extensive tumor and blood sample collection to explore potential markers to identify candidates for combining chemotherapy with PD-1 inhibition. This evidence concerns the gene PDCD1 and neoplasm.